Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy

Cancer immunology research

Volumn 1, Issue 5, 2013, Pages 309-319

  Workenhe, Samuel T ^a   Pol, Jonathan G ^a   Lichty, Brian D ^a   Cummings, Derek T ^a   Mossman, Karen L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MITOXANTRONE; ONCOLYTIC VIRUS;

ANIMAL; BAGG ALBINO MOUSE; BONE NEOPLASMS; CD8+ T LYMPHOCYTE; CELL DEATH; DRUG EFFECTS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MITOXANTRONE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OSTEOSARCOMA; RECEPTOR, ERBB-2;

EID: 84891828604     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0059-T     Document Type: Article

References (0)